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Abstract
Background: Though compliance (or adherence) problems, as well as inappropriate levothyroxine (L-T4) intake (e.g.
with meal, other drugs or certain foods that can significantly affect absorption) are very common, the issue is often
either not mentioned or even frankly denied by patients.
Case Presentation: We describe three cases of patients who presented with high TSH (ranging from about 30 to
200 mIU/l), with concomitantly either high, normal or low free thyroxine (FT4), despite treatment with high doses of
L-T4. The above mentioned problems with adjustment of L-T4 dose persisted for several months or even years.
Coeliac disease screen was negative in all cases.
In all these patients administration of a single bolus of L-T4 (1000 μg) or two doses of 1000 μg of L-T4 within 48 h
resulted in a quick increase in FT4 (thus confirming proper absorption) and in normalization of TSH within a week.
No adverse effects of administration of these high doses of L-T4 were observed.
Conclusions: Our data support the efficacy, as well as safety of administration of single bolus of high dose L-T4
as a test for possible compliance/adherence problems.
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Background
Compliance (also termed adherence) problems, as well
as inappropriate intake of levothyroxine (L-T4) (e.g. with
meal, other drugs or certain foods that affect absorption)
are considered to be very common, yet, the issue is typ-
ically either not mentioned, or even denied by patients.
Precise incidence of compliance problems is not known,
but may be quite high. For instance, Morris et al. [1] re-
port that about 40 % of 74 pediatric patients (median
age 12.5 years) had at least one episode of non-
compliance following thyroidectomy. Here we present
three cases, where suspected poor compliance was con-
firmed by a high dose L-T4 test.
Patient I
A 22-year old male after thyroidectomy (BMI 26.1 kg/
m2) for poorly controlled Graves’ disease, complicated
by recurrent laryngeal nerve palsy and hypocalcaemia
(post-surgical hypoparathyroidism) presented with high
TSH and high free thyroxine (FT4) despite 150 μg of L-
T4 daily (Table 1). A possibility of poor compliance to
medication was raised, particularly in view of episodes of
concomitantly high TSH and high FT4 (Table 1). He was
admitted to hospital, where 1000 μg of L-T4 was admin-
istered without any side-effects. This was followed by
normalization of TSH and FT4 (Table 2). Subsequently,
he has never turned up for any future follow-up.
Patient II
Twenty-one year old female (weight about 55 kg, BMI
21.2 kg/m2) presented with very high TSH (198.76 μIU/
ml during hospital admission, previous TSH in the out-
patient setting 378 μIU/ml) despite taking 175 μg of
L-T4. Problems with adequate control dated back about
6 years with massive swings in TSH concentrations (e.g.
TSH 92.58 μIU/ml and 23.3 on 200 μg of L-T4, and
2 years later TSH 0.062 μIU/ml on 150 μg of L-T4). Di-
lution test (Table 3) showed no evidence of interference,
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with similar post-dilution recovery concentrations.
Levothyroxine (1000 μg) was administered with quick
reduction of TSH and evidence of good absorption of L-
T4 (a rise in FT4 from 1.13 ng/dl to 2.72 ng/dl within
10 h) -Table 4. She eventually admitted to missing occa-
sional tablets and more often to taking L-T4 with or
even after breakfast with morning coffee. About
2 months post discharge she presented with suppressed
TSH. The dose of L-T4 was gradually decreased to
125 μg/day.
Patient III
Fifty-eight year old obese woman (BMI about 35 kg/m2)
presented with high TSH and low FT4 despite taking
high dose of L-T4 (300 μg/day). She had a history of thy-
roidectomy for Graves’s disease about 3 years before,
and according to documentation she was rather erratic
in taking her methimazole tablets, that was one of the
reasons to proceed with thyroid surgery. She also had a
history of cholecystectomy for cholelithiasis and was
waiting for appointment with gastroenterologists be-
cause of abnormal liver function tests (Table 5). She was
taking Calcium and vitamin D preparations for osteopor-
osis prophylaxis. She denied excessive alcohol consump-
tion. Two doses of 1000 μg of L-T4 were administered
within 48 h without any adverse effects. This was
followed by marked improvement of her well-being, as
well as her thyroid function tests results (Table 6). She
was told that it was essential to take her L-T4 tablets at
least 60 min before breakfast (that she had not done be-
fore). Two months post discharge she had a low-normal
FT4 [0.97 ng/dl (referenced range 0.93–1.70)] and
slightly raised TSH [12.06 mIU/l (reference range 0.27–
4.20)]. She did not turn up for her follow-up appoint-
ment scheduled 1 week after her blood test.
Discussion
Our cases demonstrate that administration of a single
high dose of L-T4 can be useful in cases of suspected
poor compliance. Due to a relatively long half-life of L-
T4 an idea of once-weekly administration regimen had
been raised before and tested with a considerable suc-
cess [2, 3], where single doses of L-T4 oscillated around
1000–1500 μg. Though administration of such high dose
of L-T4 might be thought to be potentially associated
with side-effects, such as heart palpitations, angina, etc.,
the test was reported to be surprisingly well tolerated
[4–6]. Furthermore, some patients actually preferred a
weekly, rather than a daily L-T4 administration [4, 6]. In
accordance with these data we did not observe any ad-
verse effects of administration of these high doses of L-
T4, while some authors (KCL) participated in a study
where even a higher dose of L-T4 (2000 μg) was admin-
istered without any side-effects, while testing for hetero-
philic antibodies interference [7]. According to the
literature data, the upper range of age of patients tested
for possible non-adherence with high dose L-T4 was as
high as 88 years [6]. Also current FDA bioequivalence
Table 1 Thyroid function tests of 22-year old male prior to L-T4 test
Date TSH (μIU/ml) Reference range (μIU/ml) FT4 (ng/dl) Reference range (ng/dl) Free triiodothyronine (FT3) (pg/ml) Reference range (pg/ml)
06.01 <0.005a 0.27–4.2 1.21a 0.93–1.7 7.35 2.6–4.4
18.03 - 0.27–4.2 2.11 0.93–1.7 9.28 2.6–4.4
10.05 - 0.27–4.2 0.583a 0.93–1.7 3.98 2.6–4.4
17.06a 80.74 0.27–4.2 - 0.93–1.7 - 2.6–4.4
06.09 15.77 0.27–4.2 1.74 0.93–1.7 - 2.6–4.4
23.09 19.22 0.27–4.2 - 0.93–1.7 - 2.6–4.4
03.11 27.84 0.27–4.2 1.42 0.93–1.7 - 2.6–4.4
10.11 14.53 0.27–4.2 1.93 0.93–1.7 3.99 2.6–4.4
aresults after thyroidectomy in June 2010
Table 2 1000 μg L-T4 test in Patient I
Date TSH (μIU/ml) Reference range (μIU/ml) FT4 (ng/dl) Reference range (ng/dl) FT3 (pg/ml) Reference range (pg/ml)
Day 0a 18.92 0.27–4.2 1.54 0.93–1.7 3.06 2.6–4.4
Day 1 8.79 0.27–4.2 4.32 0.93–1.7 4.69 2.6–4.4
Day 2 6.87 0.27–4.2 3.36 0.93–1.7 4.69 2.6–4.4
Day 3 2.34 0.27–4.2 2.58 0.93–1.7 4.26 2.6–4.4
Day 4 1.40 0.27–4.2 2.22 0.93–1.7 3.84 2.6–4.4
Day 5 1.16 0.27–4.2 1.82 0.93–1.7 4.93 2.6–4.4
Day 6 2.76 0.27–4.2 1.65 0.93–1.7 3.45 2.6–4.4
areceived 1000 μg of L-T4 (Euthyrox N®) as a single fasting dose
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guidelines require that supra-therapeutic doses of L-T4
(around 600 μg) should be administered in studies aim-
ing to assess pharmacokinetics of L-T4 preparations [8].
One must be, however, aware that despite an excellent
tolerance data, the number of patients participating in
weekly L-T4 studies was still relatively small (e.g. 12 pa-
tients in 3, or 23 patients in 6), so that a caution must
be applied in case of patients with a history of active is-
chaemic heart disease (e.g. confirmed unstable angina,
after coronary artery by-pass grafts, etc.).
Another issue pertains to the very definition of non-
compliance or non-adherence. In case of L-T4, this may
involve both missing tablets completely (most likely in
Patient I), or taking them tablets inappropriately, e.g.
with meal or after meal with concomitant ingestion of
coffee, etc. (Patients II and III). For instance, Bach-
Huynh et al. [9] demonstrated that even with full com-
pliance, an ingestion of L-T4 tablets within 20 min of
breakfast results in more than 100 % increase in mean
TSH concentrations (1.54 mIU/l versus 3.74 mIU/l), as
well as a dispersion of measured TSH values up to
around 19 mIU/l. Though in a seminal study of Wenzel
and Kirschsieper [10] ingestion of L-T4 was reduced
down to 64 % (for a 100 μg dose), if taken with food,
even lower values (down to 40 %) are quoted [8]. Certain
food and drinks affect absorption of L-T4. In particular
this includes dietary fibres (e.g. in muesli, corn-flakes),
coffee, grapes, soybeans and papaya fruits [11], of which
the first two are commonly consumed with breakfast in
Poland. Calcium salts, currently commonly combined
with vitamin D, as a part of osteoporosis prophylaxis,
and often taken with food during breakfast (applicable
in our Patient III), can also significantly impair L-T4
absorption [12]. Absorption of L-T4 is also decreased in
cases of higher gastric pH, such as atrophic gastritis, use
of proton pump inhibitors, as well as Helicobacter pylori
infection [8, 11]. Intestinal, as well as hepatic diseases
are associated with worse absorption of L-T4. This might
be relevant to our Patient III, as she had previous chole-
cystectomy, abnormal liver function tests and was taking
Calcium and vitamin D preparations for osteoporosis
prophylaxis. She was referred for gastroenterological
consultation with view of performing an endoscopic
retrograde cholangiopancreatography (ERCP). There is
also a well known phenomenon of enterohepatic circula-
tion of thyroid hormones [13], that was also therapeutic-
ally explored for instance for treatment of thyrotoxicosis
in humans [14, 15]. In particular, biliary disease might
have potentially influenced reabsorption of thyroid hor-
mones, particularly in a hypothyroid state, as there are
data [13] that hypothyroid rats had diminished levels of
bile acid synthesis and biliary secretion of cholesterol
and phospholipid. In such settings, a single dose triiodo-
thyronine (T3) injection produced a 13-fold increase in
bile cholesterol secretion and a 3-fold increase in
phospholipid secretion, both initiated 12 h after T3 ad-
ministration [13]. It should mentioned, however, that
though unresolved issue of abnormal liver function
might have contributed to a decrease of L-T4 absorption
in Patient III, it was unlikely to be a sole factor respon-
sible for clinical picture observed in this patient. This is
because of a striking increase of FT4 concentrations
(from 0.36 ng/dl, to 1.18 ng/dl) at about 10 h post inges-
tion of 1000 μg of L-T4 (on an empty stomach with
breakfast delayed to 60 min post ingestion). This con-
firms an adequate absorption of L-T4 tablets on condi-
tion that they were swallowed in an appropriate fashion.
Indeed Walker et al. [6] studied absorption of L-T4
















Day 0 >100 0.27–4.2 1.13 0.93–1.7 2.01 2.6–4.4
Day 0a
(6.00 PM)
37.91 0.27–4.2 2.72 0.93–1.7 2.10 2.6–4.4
Day 1 25.54 0.27–4.2 1.99 0.93–1.7 2.96 2.6–4.4
Day 2 10.37 0.27–4.2 1.82 0.93–1.7 3.22 2.6–4.4
Day 3 7.82 0.27–4.2 1.58 0.93–1.7 3.09 2.6–4.4
areceived 1000 μg of L-T4 (Euthyrox N®) as a single fasting dose
Table 3 Serial dilution test of 21 year old female with very high TSH
Date TSH (μIU/ml) Dilution 4× Dilution 8× Dilution 16× Dilution 32×
Day 0 >100 198.76 (4 × 48.94) 199.44 (8 × 24.93) 209.8 221.12
Recovery: (16 × 13.11) (32 × 6.91)
100.3 % Recovery: Recovery:
(199.44 × 100 %/198.76) 105.5 % 111.2 %
Table 5 Liver function of 58-year old women with high TSH on
300 μg of L-T4




Alkaline phosphatase 87 38–126
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given as a single weekend dose) at 60, 120, 180 and
240 min after L-T4 bolus, and concluded that in 82 % of
cases the maximal rise of FT4 occurred as soon as at
120 min. Hence, there is a possibility that in our patient
FT4 concentrations might be even higher if tested at an
earlier timing. It might be also interesting to mention,
that Australian authors [16] proposed a variation of L-T4
absorption test that involves co-administration of para-
cetamol tablets for detection of cases of deliberate avoid-
ance of tablet swallowing.
Conclusions
In summary, our data support the efficacy, as well as
safety of administration of single bolus of high dose L-T4
in some patients who fail to normalize their thyroid
function tests, despite prolonged attempts to adjust their
L-T4 dose in the outpatient settings. To the best of our
knowledge this is the first paper in Polish medical litera-
ture describing clinical application of bolus high dose
L-T4 test for possible non-compliance problems.
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a received 1000 μg of L-T4 (Euthyrox N®) as a single fasting dose
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